Cubist Systematic Strategies LLC Sells 65,030 Shares of Dermira Inc (NASDAQ:DERM)

Share on StockTwits

Cubist Systematic Strategies LLC trimmed its holdings in Dermira Inc (NASDAQ:DERM) by 64.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,821 shares of the biopharmaceutical company’s stock after selling 65,030 shares during the period. Cubist Systematic Strategies LLC’s holdings in Dermira were worth $342,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of DERM. Dimensional Fund Advisors LP grew its position in Dermira by 2.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 943,421 shares of the biopharmaceutical company’s stock worth $6,783,000 after acquiring an additional 22,816 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in Dermira by 68.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 763,590 shares of the biopharmaceutical company’s stock worth $10,347,000 after acquiring an additional 310,551 shares in the last quarter. GYL Financial Synergies LLC bought a new stake in Dermira in the first quarter worth approximately $288,000. Fox Run Management L.L.C. bought a new stake in Dermira in the second quarter worth approximately $120,000. Finally, Aperio Group LLC grew its position in Dermira by 24.4% in the second quarter. Aperio Group LLC now owns 14,690 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 2,878 shares in the last quarter. 94.53% of the stock is owned by institutional investors.

Several research firms have commented on DERM. BidaskClub downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research report on Tuesday, October 1st. Zacks Investment Research upgraded shares of Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price objective for the company in a research note on Wednesday. Two analysts have rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.36.

In other news, CEO Thomas G. Wiggans acquired 23,419 shares of Dermira stock in a transaction dated Monday, August 19th. The stock was acquired at an average cost of $8.54 per share, for a total transaction of $199,998.26. Following the completion of the purchase, the chief executive officer now owns 39,666 shares of the company’s stock, valued at $338,747.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Matthew K. Fust sold 6,000 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $8.77, for a total transaction of $52,620.00. Following the completion of the sale, the director now owns 11,051 shares of the company’s stock, valued at $96,917.27. The disclosure for this sale can be found here. 12.40% of the stock is currently owned by insiders.

Shares of Dermira stock opened at $5.69 on Friday. The firm has a fifty day simple moving average of $7.59 and a 200-day simple moving average of $9.49. The company has a debt-to-equity ratio of 4.95, a quick ratio of 8.08 and a current ratio of 8.42. Dermira Inc has a 1-year low of $5.30 and a 1-year high of $15.48.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.57. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%. The business had revenue of $66.65 million during the quarter, compared to analysts’ expectations of $34.16 million. Equities research analysts anticipate that Dermira Inc will post -4.42 earnings per share for the current fiscal year.

Dermira Company Profile

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

See Also: Why Invest in High-Yield Dividend Stocks?

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.